Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027819 (
neuroblastoma
)
27,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
p73
is a candidate tumor suppressor and imprinted gene that shares significant homology with the p53 gene. It is located on 1p36, a region frequently deleted in
neuroblastoma
and other tumors. To investigate the pattern of inactivation of this gene in human lymphomas, we studied 59 tumors to identify abnormal methylation in exon 1 and loss of heterozygosity (LOH) at this locus.
p73
was methylated in 13/50 (26%) B cell lymphomas. There was no evidence of
p73
methylation in the 9 T cell lymphomas analyzed. Burkitt's lymphomas showed the highest proportion of methylated cases (36%), although this alteration also affected other aggressive lymphomas such as diffuse large cell and some marginal zone lymphomas. LOH at the
p73
locus was detected in 4/34 (11%) B and 1/9 (11%) T cell lymphomas. The
p73
expression analysis showed absence or low level of
p73
product in methylated lymphomas, whereas
p73
was always detected in unmethylated tumors. We found monoallelic expression in normal peripheral blood samples, consistent with imprinting. None of the tumors showed LOH and methylation of the remaining allele simultaneously, suggesting that alteration of the expressed allele could lead to the total inactivation of the gene. Our results show that deletion or methylation of the
p73
gene could be important mechanisms in suppressing
p73
expression in B cell non-Hodgkin's lymphomas.
...
PMID:Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. 1235 28
To better understand whether the p53-related
p73
gene could induce neuronal apoptosis, we tested whether
p73
induced cell killing in three neuronal cell lines and whether apoptosis could be inhibited by p35, a baculovirus-encoded protein that blocks caspase 3. Recombinant adenoviruses carrying the hemagglutinin (HA)-tagged p73beta or p35, or the green fluorescent protein gene driven by the cytomegalovirus immediate-early promoter were constructed, and used to infect human SK-N-AS and SK-N-SH
neuroblastoma
, and rat PC12 pheochromocytoma cells. Infection with Adp73beta virus resulted in p73beta over-expression and substantial reduction of cell viability due to apoptosis in all three neuronal cell lines as compared with the control AdGFP virus. These results indicate that p73beta over-expression in neuronal cells could induce apoptotic cell death regardless of the endogenous expression of
p73
. The
p73
effect was partially blocked by co-expression of the wild-type p35, suggesting caspase-mediated cell killing. Insertion of a hemagglutinin (HA) tag at the N-terminus of p35 markedly reduced its ability to inhibit the
p73
effect compared with the wild-type p35, while insertion of an HA tag to the C-terminus of p35 had no appreciable effect. Taken together, our results suggest that the N-terminal structure of p35 is critical for its anti-apoptotic activity on
p73
-induced apoptosis in neuronal cells.
...
PMID:Induction of apoptosis by the p53-related p73 and partial inhibition by the baculovirus-encoded p35 in neuronal cells. 1275 1
In human
neuroblastoma
(NB), wild type p53 protein does not elicit its archetypal human tumor suppressive activity so far described. To elucidate this alteration, substantial investigations using NB cell lines have underscored p53 protein nuclear localization defect and/or inappropriate conformation, but no definitive evidence has been provided so far.
p73
, the first homologue of the p53 gene, locates at the 1p36.3 locus, which is known to be deleted in various human tumors including NB. Unlike p53 mRNA, which specifies a single protein, p73alpha mRNAs encode two types of isoform (TAp73alpha and DeltaNp73alpha) resulting from the use of two different promoters, and eliciting or lacking NH(2)-terminal transactivation domain, respectively. DeltaNp73alpha inhibits p53 pro-apoptotic function in murine developing neurons and is abundantly expressed in human undifferentiated NB tumors. However, critical issues have been raised regarding p73alpha isoform roles, and their possible link to p53 are yet to be clarified in human NB using adenoviral infection approach.
...
PMID:When p53 needs p73 to be functional - forced p73 expression induces nuclear accumulation of endogenous p53 protein. 1288 Sep 67
p73
, mapped to 1p36.2-3, is a p53-related tumor suppressor but is also induced by the oncogene products such as E2F1, raising a question whether
p73
is a tumor suppressor gene or oncogene.
p73
has several splicing variants including DeltaNp73 which lacks the NH(2)-terminal transactivation domain. In developing neurons, DeltaNp73 is expressed abundantly and seems to inhibit the pro-apoptotic function of p53. However, the role of TAp73 and DeltaNp73 as well as their regulatory mechanism in cell growth and differentiation of
neuroblastoma
cells are poorly understood. We have found that TAp73 directly activates the transcription of endogenous DeltaNp73 by binding to the TAp73-specific target element located at position-76 to 57 within the DeltaNp73 promoter region. DeltaNp73 was physically associated with TAp73alpha, TAp73beta and p53, and inhibited their transactivation activities when used reporters of Mdm2, Bax or DeltaNp73 itself in SAOS-2 cells. Overexpression of DeltaNp73 in SH-SY5Y
neuroblastoma
cells promoted cell survival by competing with p53 and TAp73 itself. Thus, our results suggest that the negative feedback regulation of TAp73 by its target DeltaNp73 is a novel autoregulatory system for modulating cell survival and death, that is also functioning in
neuroblastoma
cells.
...
PMID:Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells. 1288 Sep 68
The
p73
gene is a p53 homologue localized at 1p36.3, a chromosomal region frequently deleted in
neuroblastoma
.
p73
was originally considered an oncosuppressor gene. However, it was soon realized that its mode of action did not resemble that of a classic anti-oncogene. The recent discovery of N-terminal truncated isoforms, with oncogenic properties, showed that
p73
has a 'two in one' structure. Indeed, the full-length variants are strong inducers of apoptosis while the truncated isoforms inhibit the pro-apoptotic activity of p53 and of the full-length
p73
. This review summarizes some aspects of
p73
biology with particular reference to its possible role in
neuroblastoma
.
...
PMID:Biological and clinical role of p73 in neuroblastoma. 1288 Sep 69
p73
, the first p53 gene homologue, encodes an array of
p73
proteins including
p73
alpha full-length (TAp73 alpha) and amino-truncated isoforms (Delta Np73 alpha), two proteins with opposite biological functions. TAp73 alpha can induce tumor suppressive properties, while Delta Np73 alpha antagonizes p53 as well as TAp73 in a dominant-negative manner. In human malignant neuroblasts, p53 protein is wild-type but known to be excluded from the nucleus, therefore disabling its function as a tumor suppressor. The present study investigates whether there is a functional link between
p73
isoforms and p53 in
neuroblastoma
. Experiments were performed on two
neuroblastoma
cell lines differing in their p53 status, e.g. wild-type p53 SH-5Y5Y cells and mutated p53 IGR-N-91 cells. Data indicate that (i) both TA- and Delta N-
p73
alpha enhance p53 protein level in SH-SY5Y cells, whereas level remains unchanged in IGR-N-91 cells; (ii) only in SH-SY5Y cells does forced TAp73 alpha overexpression markedly induce nuclear accumulation of p53 protein; (iii) p21 protein expression is increased in both cell lines infected with TAp73, suggesting that, in IGR-N-91 cells, p21 is induced by
p73
through a p53-independent pathway; (iv) in the SHSY5Y cell line, Btg2 expression is strongly enhanced in cells overexpressing TA, and to a lesser extent in cells overexpressing Delta N. Taken together our results suggest that TAp73 may restore p53 function in NB with wild-type nonfunctional p53, but not in NB with mutated p53.
...
PMID:Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line. 1467 79
Neuroblastomas
are the most frequently occurring solid tumors in children under 5 years. Spontaneous regression is more common in neuroblastomas than in any other tumor type, especially in young patients under 12 months. Unfortunately, the full clinical spectrum of neuroblastomas also includes very aggressive tumors, unresponsive to multi-modality treatment and accounting for most of the pediatric cancer mortalities under 5 years of age. It is generally emphasized that more than one biological entity of
neuroblastoma
exists. Structural genetic defects such as amplification of MYCN, gain of chromosome 17q and LOH of 1p and several other chromosomal regions have proven to be valuable as prognostic factors and will be discussed in relation to their clinical relevance. Recent research is starting to uncover important molecular pathways involved in the pathogenesis of neuroblastomas. The aim of this review is to discuss several important aspects of the biology of the neuroblast, such as the role of overexpressed oncogenes like MYCN and cyclin D1, the mechanisms leading to decreased apoptosis, like overexpression of BCL-2, survivin, NM23, epigenetic silencing of caspase 8 and the role of tumor suppressor genes, like p53,
p73
and RASSF1A. In addition, the role of specific proteins overexpressed in neuroblastomas, such as the neurotrophin receptors TrkA, B and C in relation to spontaneous regression and anti-angiogenesis will be discussed. Finally, we will try to relate these pathways to the embryonal origin of neuroblastomas and discuss possible new avenues in the therapeutic approach of future
neuroblastoma
patients.
...
PMID:Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. 1469 5
p73
gene is a new member of the tumor suppressor gene p53 family. They are similar in the structure and function of the coding protein, but they also have notable distinctions in other aspects. Many studies have shown that the abnormal
p73
gene is associated with
neuroblastoma
, malignant melanoma, prostatic carcinoma, and lung cancer, et al. Recently, many studies have demonstrated that
p73
gene may involve the occurrence and development of a portion of the digestive system carcinoma. This review summarized the present conditions of the
p73
gene and its correlation with the occurrence, development, prognosis, and expression in the digestive system carcinoma. We suggested that the further study about the
p73
gene may be helpful to recognize the nature of the carcinoma and bring wish to overcome it finally.
...
PMID:[Study progress of p73 gene in digestive system carcinoma]. 1472 Mar 84
Topoisomerase I inhibitors, such as CPT-11, are potent anticancer drugs against
neuroblastoma
(NB). Differentiating agents, such as retinoids, improve the survival of children with metastatic NB. To characterize the biological effects associated with exposure to CPT-11 in vivo, athymic mice bearing a human NB xenograft, named IGR-NB8 and characterized as an immature NB with poor prognostic markers, were treated with CPT-11. Prolonged stable disease was observed, resulting in an overall tumor growth delay of 115 days. During treatment, tumors differentiated into ganglioneuroblastomas (GGNB), which reverted into an immature phenotype when treatment was discontinued. In contrast, 13-cis retinoic acid failed to induce differentiation of IGR-NB8 in vivo. Tumor differentiation was associated with decreased N-myc expression, induction of
p73
expression in the perinuclear area and cytoplasm, and a dramatic 35-fold decrease in topoisomerase I (topo I) catalytic activity. The full-length Mr 100,000 topo I protein was present in both pre and post-treatment immature NB xenografts. In contrast, differentiated GGNBs did not contain the Mr 100,000 protein but an intense Mr 48,000 topo I fragment. Furthermore, redistribution of the Mr 48,000 and 68,000 forms to the cytoplasm was observed in differentiated tumors. The same pattern of topo I expression and catalytic activity was observed in NBs and GGNBs obtained from pediatric patients. Our data suggest that prolonged in vivo exposure to CPT-11 induces differentiation of NB xenografts, which is associated with truncation of the topo I enzyme, relocation of the degraded forms to the cytoplasm, and decreased catalytic activity.
...
PMID:In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations. 1512 63
p73
, the homologue of p53, is a nuclear protein whose ectopic expression, in p53+/+ and p53-/- cells, recapitulates the most well-characterized p53 effects, such as growth arrest, apoptosis and differentiation. Unlike p53, which is mutated in half of human cancers,
p73
is rarely mutated. However, altered expression of the
p73
gene has been reported in
neuroblastoma
, lung cancer, prostate cancer and renal cell carcinoma. To investigate the potential involvement of
p73
in acute myeloid leukemias (AMLs), we analyzed 71 samples from AML patients for the expression pattern of N-terminal transactivation-p73alpha (TA-p73alpha), its spliced isoforms and N-terminal-deleted-
p73
transcripts (DeltaN-p73). We detected
p73
gene expression in AML irrespective of FAB (French-American-British) subtypes. Notably, the analysis of DeltaN-
p73
expression, which has been reported to inactivate both p53 and
p73
antitumor effects, revealed a rather peculiar pattern. In fact, DeltaN-
p73
transcript and protein were detectable in 27/28 (96.4%) cases of M0, M1, M2, M4, M5 and M6 AML and in 13/41 (31.7%) cases of PML-RARalpha-positive M3 AML (P<0.01). Thus, the distinct gene expression profile of
p73
further supports the notion that acute promyelocytic leukemia is a biologically different subset of AML.
...
PMID:Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. 1538 38
<< Previous
1
2
3
4
5
6
7
Next >>